Company / Capital Expenditures
Avalo Therapeutics, Inc. Capital Expenditures History
FY2017-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$95.0K
FY2022
5-year range
$95.0K / $113.0K
FY2018-FY2022
Trend
-15.9%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 6 years, ranging from $23,325 in FY2017 to $564,415 in FY2018.
Based on SEC 10-K filings.
$95,000 in FY2022 with a 5-year CAGR of +32.4%.
Improved from $63,000 to $95,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -28.7%
- 5-Year CAGR
- +32.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +32.4%, indicating consistent growth.
- In FY2022, capital expenditures decreased 15.9% year-over-year.
- Peak capital expenditures was recorded in FY2018.
- Lowest capital expenditures in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $95.0K | -15.9% |
| FY2021 | $113.0K | +79.4% |
| FY2020 | $63.0K | -76.0% |
| FY2019 | $262.0K | -53.6% |
| FY2018 | $564.4K | +2319.8% |
| FY2017 | $23.3K | - |
As of FY2022 · SEC Form 10-K · Last checked Jun 21, 2026